Champions Oncology Q4 2024 Adj EPS $0.01 Beats $(0.16) Estimate, Sales $14.001M Beat $12.692M Estimate
Champions Oncology Q4 2024 Adj EPS $0.01 Beats $(0.16) Estimate, Sales $14.001M Beat $12.692M Estimate
champions oncology 2024年第四季每股收益$0.01，超過$(0.16)的預期，銷售額爲1.4億美元，超過預期的1.2692億美元。
Champions Oncology (NASDAQ:CSBR) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.16) by 106.25 percent. This is a 105.88 percent increase over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $14.001 million which beat the analyst consensus estimate of $12.692 million by 10.31 percent. This is a 7.11 percent increase over sales of $13.071 million the same period last year.
Champions Oncology（納斯達克：CSBR）報告每股收益爲0.01美元，超過分析師預期的（0.16）美元，增長106.25％。這比去年同期每股虧損（0.17）美元增長105.88％。公司報告的季度銷售額爲1400.1萬美元，比分析師預期的1269.2萬美元增長10.31％。這是去年同期1307.1萬美元銷售額的7.11％增長。